E02H1.1 Antibody

What is E02H1.1 antibody and what are its neutralizing capabilities?

E02H1.1 is part of a class of antibodies capable of neutralizing diverse subtypes of group 1 influenza A viruses. This antibody was identified from subjects enrolled in an H5N1 DNA/MIV-prime-boost influenza vaccine trial, where researchers sorted hemagglutinin cross-reactive memory B cells . The antibody demonstrates potential as a component for universal influenza vaccine development due to its broad neutralizing capabilities across viral subtypes.

When conducting initial characterization studies, researchers should:

• Verify specificity using ELISA against recombinant hemagglutinin proteins

• Confirm cross-reactivity profiles against multiple influenza subtypes

• Assess binding affinity using surface plasmon resonance or biolayer interferometry

How should researchers properly store and handle E02H1.1 antibody to maintain its activity?

While specific storage recommendations for E02H1.1 are not provided in the available literature, antibody stability generally depends on proper handling techniques that minimize degradation. For research antibodies used in influenza studies, these methodological approaches are recommended:

• Store concentrated antibody preparations at -80°C for long-term storage

• Maintain working aliquots at -20°C with minimal freeze-thaw cycles (≤5)

• When thawed for experiments, keep samples at 4°C for short-term use

• Monitor protein stability using techniques like size-exclusion chromatography (SEC)

Researchers can employ techniques similar to those used for other therapeutic antibodies, such as using "G3000SWXL column (Tosoh Corp, 7.8 mm i.d.*30 cm)" for SEC analysis, with a mobile phase consisting of "25 mM sodium phosphate (pH 6.5) and 300 mM sodium chloride" .

What analytical techniques are recommended for assessing the thermal stability of E02H1.1?

For comprehensive thermal stability assessment of antibodies like E02H1.1, researchers should implement differential scanning calorimetry (DSC) and intrinsic fluorescence measurements to determine melting temperature (Tm) and aggregation temperature (Tagg).

A methodological approach based on available literature includes:

• Implement a linear thermal ramp from 25 to 95°C at a rate of 1°C/min

• Monitor changes in intrinsic fluorescence using 266 nm laser excitation

• Analyze the barycentric mean (BCM) between 300-430 nm

• Track changes in static light scattering by measuring intensities at 266 and 473 nm

• Determine Tm values from the maximum gradient of the BCM versus temperature traces

This comprehensive thermal profiling provides critical information about antibody stability under various experimental conditions, essential for optimizing storage and handling protocols.

How can researchers accurately determine the binding kinetics of E02H1.1 to viral targets?

Biolayer interferometry offers a robust approach for determining binding kinetics of antibodies like E02H1.1 to influenza hemagglutinin targets. Based on methodologies used for similar antibodies:

• Immobilize the antibody (at 50 μg/mL) onto FAB2G sensors

• Prepare serial dilutions of target protein (e.g., 20 nM to 1.25 nM)

• Monitor binding for 60 seconds and dissociation for an additional 60 seconds

• Calculate association rate (kon), dissociation rate (koff), and equilibrium dissociation constant (KD)

• Compare binding parameters across different influenza subtypes to establish cross-reactivity profiles

This approach provides quantitative data on antibody-antigen interactions that can inform epitope mapping and neutralization mechanisms.

How should E02H1.1 be incorporated into neutralization assays for influenza virus?

When designing neutralization assays with E02H1.1, researchers should consider this methodological framework:

• Prepare serial dilutions of E02H1.1 antibody (starting at ~50 μg/mL)

• Pre-incubate diluted antibody with standardized viral inoculum (100-200 TCID50)

• Add antibody-virus mixture to appropriate cell lines (MDCK cells for influenza)

• Incubate for 48-72 hours under controlled conditions

• Assess viral inhibition through cytopathic effect observation or hemagglutination assays

• Calculate IC50 values (antibody concentration providing 50% inhibition)

For comprehensive evaluation, include multiple influenza subtypes from both group 1 and group 2 to verify the broad neutralizing capacity suggested by previous research .

What is the role of E02H1.1 in vaccine development research?

E02H1.1 represents a valuable research tool for universal influenza vaccine development given its broad neutralizing capabilities. Researchers exploring vaccine applications should consider:

• Epitope mapping to identify conserved regions recognized by E02H1.1

• Structure-based immunogen design to elicit similar broadly neutralizing antibodies

• B-cell repertoire analysis to understand antibody lineage development

• Prime-boost vaccination strategies similar to the H5N1 DNA/MIV approach that elicited E02H1.1

This research direction is particularly promising as "antibodies capable of neutralizing divergent influenza A viruses could form the basis of a universal vaccine" .

What controls and validation steps are essential when using E02H1.1 in ELISA-based assays?

For robust ELISA experiments utilizing E02H1.1, researchers should implement these methodological controls:

• Include positive control antibodies with known binding properties to the same antigen

• Incorporate isotype-matched negative control antibodies lacking specificity for the target

• Develop a standard curve using purified antigen at concentrations ranging from 0-1000 ng/mL

• Apply appropriate dilution factors for test samples (reference Supplementary Table methodology)

• Include quality control samples at low, medium, and high dilutions (e.g., 1:5000, 1:15000, and 1:45000)

• Perform technical replicates (minimum triplicate) for all samples and controls

• Calculate results using appropriate statistical methods, reporting values >1 ppm as round numbers and keeping one significant digit for results <1 ppm

This rigorous approach ensures reliable quantitative data and minimizes technical variability.

How can researchers minimize interference from host cell proteins when working with recombinant E02H1.1?

When working with recombinant antibodies like E02H1.1, host cell protein (HCP) contamination can interfere with experimental results. Researchers should:

• Implement CHO HCP ELISA to quantify residual host cell proteins in antibody preparations

• Dilute samples appropriately based on expected HCP concentration (see Supplementary Table 1 methodology)

• Include proper controls such as HCP quality control samples at various dilutions (1:5000, 1:15000, and 1:45000)

• Add calibration standards, test samples, assay controls, and anti-CHO:HRP conjugate to anti-CHO coated microtiter strips

• Measure absorbance at 450 nm and 650 nm

• Calculate HCP concentration in ppm using the formula: HCP = (1 (ng/mL) * dilution factor)/sample concentration (mg/mL)

• Report results as undetectable if below the limit of quantification (1 ng/mL)

This approach minimizes experimental interference from HCPs, which "are exogenous antigens for humans" and "are found to be associated with allergic reaction" .

How can E02H1.1 be used to investigate antibody-dependent cellular mechanisms in influenza immunity?

To investigate potential antibody-dependent cellular mechanisms of E02H1.1, researchers should:

• Isolate PBMCs from healthy volunteers using Ficoll-Paque density gradient centrifugation

• Culture cells in appropriate media (RPMI 1640 containing 10% FBS) at 37°C

• Derive human peripheral monocyte-derived macrophages (HPMMs) from PBMCs

• Seed HPMMs at optimal density (e.g., 1×10^4 cells per well) in presence of cytokines like IFN-γ (50 ng/mL)

• Add target cells expressing the relevant viral proteins at appropriate ratios (e.g., 3×10^4 cells per well)

• Stimulate HPMMs with E02H1.1 at various concentrations (0.05, 0.5, or 5 μg/mL)

• Include appropriate controls (isotype control antibodies, positive stimulation controls like LPS)

• After incubation (24 hours), collect supernatants and quantify cytokine production using ELISA kits

• Analyze data to determine if E02H1.1 induces proinflammatory responses

These experiments will help determine whether E02H1.1 triggers antibody-dependent effector functions that could contribute to its protective capacity.

What structural analysis techniques best reveal the epitope binding characteristics of E02H1.1?

For comprehensive epitope mapping of E02H1.1, researchers should employ multiple complementary techniques:

• X-ray crystallography of antibody-antigen complexes to determine atomic-level interactions

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS) to identify regions of altered solvent accessibility upon binding

• Alanine scanning mutagenesis to identify critical residues for binding

• Competitive binding assays with known epitope-specific antibodies

• Electron microscopy of antibody-antigen complexes for visualization of binding orientation

These analyses are critical for understanding why E02H1.1 can neutralize diverse influenza subtypes and could inform structure-based vaccine design efforts targeting conserved epitopes.